Fevipiprant, a prostaglandin D2 receptor 2 antagonist, works by preventing inflammatory cells from reaching a patient's airways reduces the frequency of severe attacks by half, BBC News and The Telegraph reported Friday. Patients who have uncontrolled asthma and took part in the trial told researchers that their symptoms had improved drastically .

"A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall, and CT scans of the chest to give a complete picture of how the new drug works," study author Christopher Brightling, a clinical professor in respiratory Medicine at the University of Leicester, told The Telegraph.
"Most treatments might improve some of these features of the disease, but with Fevipiprant improvements were seen with all of the types of tests," Brightling added. "This new treatment could help stop preventable asthma attacks, reduce hospital admissions, and improve day-to- day symptoms- making it a 'game changer' for future treatment."